Screener
TG Therapeutics TGTX SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Selling, general and administrative: | ||||
| Stock-based compensation | 19,805 | 12,044 | 34,880 | 23,684 |
| Other selling, general and administrative | 62,325 | 43,541 | 135,467 | 82,232 |
| Total selling, general and administrative | 82,130 | 55,585 | 170,347 | 105,916 |
| Total costs and expenses | 218,661 | 106,305 | 388,784 | 218,539 |
| Operating income | 21,674 | 34,843 | 56,469 | 43,465 |
| Other expense (income): | ||||
| Interest expense | 16,572 | 6,716 | 24,238 | 13,473 |
Document
FAQ
- What is TG Therapeutics's SG&A?
- TG Therapeutics (TGTX) reported SG&A of $82.13M in Q2 2026.
- How has TG Therapeutics's SG&A changed year-over-year?
- TG Therapeutics's SG&A increased by 47.8% year-over-year, from $55.59M to $82.13M.
- What is the long-term trend for TG Therapeutics's SG&A?
- Over 4 years (2021 to 2025), TG Therapeutics's SG&A has grown at a 16.0% compound annual growth rate (CAGR), from $128.09M to $232.03M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about TG Therapeutics's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude